Evaluation of Pneumococcal Vaccine Formulations in Young Adults
Phase 1
Completed
- Conditions
- Infections, Streptococcal
- Interventions
- Biological: Pneumococcal vaccine GSK2189242ABiological: Pneumo 23™
- Registration Number
- NCT00707798
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of pneumococcal vaccines in young adults. Subjects will be vaccinated twice with an interval of two months.
- Detailed Description
This amendment was due to
* The addition of secondary endpoints for safety. The collection of data related to these secondary safety endpoints was already planned and the corresponding statistical analyses were described in the statistical section.
* The addition of an exclusion criterion regarding the administration of immunoglobulins and blood products. It is already included in the elimination criteria section. It impacts only immunogenicity.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 157
Inclusion Criteria
- Subjects who the investigator believes will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study.
- A male or female between, and including, 18 and 40 years old at the time of the first vaccination.
- Written informed consent obtained from the subject.
- Free of obvious health problems as established by medical history, clinical examination and clinical laboratory assessment before entering into the study.
- If the subject is female, and of child-bearing potential, she agrees to use adequate contraception and not become pregnant for the duration of the study.
Exclusion Criteria
- Previous vaccination against Streptococcus pneumoniae.
- Vaccination with diphtheria/tetanus toxoids within one month preceding the first dose of study vaccine.
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period or participation to another pharmaceutical/vaccine study.
- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
- Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of study vaccine, with the exception of the influenza vaccine which can be administered > 7 days preceding or > 7 days following each vaccine dose (after collection of 7-day safety data).
- Bacterial pneumonia within 3 years prior to 1st vaccination.
- Invasive pneumococcal disease (IPD) within 3 years prior to 1st vaccination.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
- History of thrombocytopenia or bleeding disorder.
- History of reactions or allergic disease likely to be exacerbated by any component of the vaccine.
- Current serious neurologic or mental disorders.
- Inflammatory processes such as known chronic active infections (e.g. Hepatitis B, C).
- All past or current malignancies (excluding non-melanic skin cancer) and lymphoproliferative disorders.
- Acute disease at the time of enrolment/vaccination.
- Physical examination positive for acrocyanosis, jaundice, splenomegaly.
- Acute or chronic, clinically significant anaemia, pulmonary, cardiovascular, hematologic , hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests, at the discretion of the investigator.
- Laboratory evidence of haematological abnormalities.
- Laboratory evidence of biochemical abnormalities
- Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
- Pregnant or lactating female.
- Female planning to become pregnant or planning to discontinue contraceptive precautions.
- History of chronic alcohol consumption and/or drug abuse.
- Other conditions that the principal investigator judges may interfere with study findings.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Formulation 1 Pneumococcal vaccine GSK2189242A - Formulation 2 Pneumococcal vaccine GSK2189242A - 23 valent pneumococcal vaccine Pneumo 23™ - Formulation 4 Pneumococcal vaccine GSK2189242A - Formulation 3 Pneumococcal vaccine GSK2189242A - Formulation 6 Pneumococcal vaccine GSK2189242A - Formulation 5 Pneumococcal vaccine GSK2189242A -
- Primary Outcome Measures
Name Time Method Occurrence of any vaccine related and grade 3 solicited local and general adverse events During a 7-day follow up period after each vaccine dose Occurrence of any vaccine related and grade 3 unsolicited adverse events During a 31-day follow up period after each vaccine dose Occurrence of any vaccine related serious adverse events (SAE) From Visit 1 to study conclusion Occurrence of any grade 3 laboratory abnormalities During a 7-day follow up period after each vaccine dose
- Secondary Outcome Measures
Name Time Method Occurrence of any solicited local and general adverse events During a 7-day follow up period after each vaccine dose. Occurrence of any unsolicited adverse events During a 31-day follow up period after each vaccine dose Occurrence of any haematological, biochemical, or urinary abnormalities At 1 and 7 days after each vaccine dose Anti-pneumococcal and anti-NTHi candidate vaccine antigens At Days 0, 30 and 90
Trial Locations
- Locations (1)
GSK Investigational Site
🇧🇪Gent, Belgium